No Data
No Data
Dianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference
NEW YORK and WALTHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement
Dianthus Therapeutics Enhances Incentives and Affirms Governance
Companies Like Dianthus Therapeutics (NASDAQ:DNTH) Are In A Position To Invest In Growth
H.C. Wainwright Starts Dianthus as Buy, Cites Lead Drug Candidate
Analysts' Opinions Are Mixed on These Healthcare Stocks: 60 Degrees Pharmaceuticals, Inc. (SXTP), GoodRx Holdings (GDRX) and Dianthus Therapeutics (DNTH)
Dianthus Therapeutics' DNTH103: A Potential Game-Changer in Autoimmune Disease Treatment